In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones

Journal of Immunology

Volumn 171, Issue 6, 2003, Pages 2912-2921

  Schreurs, Marco W J ^a   Scholten, Kirsten B J ^a   Kueter, Esther W M ^a   Ruizendaal, Janneke J ^a   Meijer, Chris J L M ^a   Hooijberg, Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; ONCOPROTEIN; RNA; RNA DIRECTED DNA POLYMERASE; T LYMPHOCYTE RECEPTOR; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN E7;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; MALIGNANT TRANSFORMATION; MONOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 0042333452     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.6.2912     Document Type: Article

References (59)

1. Walboomers, J. M., and C. J. Meijer. 1997. Do HPV-negative cervical carcinomas exist? J. Pathol. 181:253.
2. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518.
3. Munger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417.
4. von Knebel, D. M., C. Rittmuller, H. H. zur, and M. Durst. 1992. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer 51:831.
5. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Stacey, M. E. Boursnell, et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523.
6. Ressing, M. E., W. J. van Driel, E. Celis, A. Sette, M. P. Brandt, M. Hartman, J. D. Anholts, G. M. Schreuder, W. B. ter Harmsel, G. J. Fleuren, et al. 1996. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 56:582.
7. Evans, E. M., S. Man, A. S. Evans, and L. K. Borysiewicz. 1997. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:2943.
8. Ressing, M. E., A. Sette, R. M. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:5934.
9. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242.
10. De Bruijn, M. L., D. H. Schuurhuis, M. P. Vierboom, H. Vermeulen, K. A. de Cock, M. E. Ooms, M. E. Ressing, M. Toebes, K. L. Franken, J. W. Drijfhout, et al. 1998. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class 1-restricted protection to HPV16-induced tumor cells. Cancer Res. 58:724.
11. Shi, W., P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao. 1999. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 73:7877.
12. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
13. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
14. Youde, S. J., P. R. Dunbar, E. M. Evans, A. N. Fiander, L. K. Borysiewicz, V. Cerundolo, and S. Man. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res. 60:365.
15. Tsai, V., I. Kawashima, E. Keogh, K. Daly, A. Sette, and E. Celis. 1998. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit. Rev. Immunol. 18:65.
16. + T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods 258:111.
17. Schreurs, M. W., A. A. Eggert, C. J. Punt, C. G. Figdor, and G. J. Adema. 2000. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit. Rev. Oncog. 11:1.
18. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
19. Muller, D., K. Pederson, R. Murray, and J. A. Frelinger. 1991. A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes. J. Immunol. 147:1392.
20. Zugel, U., R. Wang, G. Shih, A. Sette, J. Alexander, and H. M. Grey. 1998. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. J. Immunol. 161:1705.
21. Bauer, M., H. Wagner, and G. B. Lipford. 2000. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol. Lett. 71:55.
22. Street, M. D., T. Doan, K. A. Herd, and R. W. Tindle. 2002. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology 106:526.
23. + T cell clones by ectopic expression of telomerase reverse transcriptase. J. Immunol. 165:4239.
24. Rufer, N., M. Migliaccio, J. Antonchuk, R. K. Humphries, E. Roosnek, and P. M. Lansdorp. 2001. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 98:597.
25. Dagarag, M., H. Ng, R. Lubong, R. B. Effros, and O. O. Yang. 2003. Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J. Virol. 77:3077.
26. + helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 101:4512.
27. + T lymphocytes in IFN-γ ELISPOT assays. J. Immunol. Methods 259:95.
28. Brady, C. S., J. S. Bartholomew, D. J. Burt, M. F. Duggan-Keen, S. Glenville, N. Telford, A. M. Little, J. A. Davidson, P. Jimenez, F. Ruiz-Cabello, et al. 2000. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401.
29. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213.
30. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
31. Kessler, J. H., B. Mommaas, T. Mutis, I. Huijbers, D. Vissers, W. E. Benckhuijsen, G. M. Schreuder, R. Offringa, E. Goulmy, C. J. Melief, et al. 2003. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 64:245.
32. Heemskerk, M. H., E. Hooijberg, J. J. Ruizendaal, M. M. van der Weide, E. Kueter, A. Q. Bakker, T. N. Schumacher, and H. Spits. 1999. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells. Cell. Immunol. 195:10.
33. de Vries, I. J., A. A. Eggert, N. M. Scharenborg, J. L. Vissers, W. J. Lesterhuis, O. C. Boerman, C. J. Punt, G. J. Adema, and C. G. Figdor. 2002. Phenotypical and functional characterization of clinical grade dendritic cells. J. Immunother. 25:429.
34. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J. Immunol. Methods 196:137.
35. Yssel, H., J. E. De Vries, M. Koken, W. Van Blitterswijk, and H. Spits. 1984. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J. Immunol. Methods 72:219.
36. Bakker, A. B., M. W. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
37. + progenitor cells isolated from healthy donor blood: growth factor combination determines proliferation rate and functional outcome. J. Leukocyte Biol. 72:321.
38. Bordignon, C., L. D. Notarangelo, N. Nobili, G. Ferrari, G, Casorati, P. Panina, E. Mazzolari, D. Maggioni, C. Rossi, P. Servida, et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470.
39. Counter, C. M., W. C. Hahn, W. Wei, S. D. Caddle, R. L. Beijersbergen, P. M. Lansdorp, J. M. Sedivy, and R. A. Weinberg. 1998. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA 95:14723.
40. Heemskerk, M. H., B. Blom, G. Nolan, A. P. Stegmann, A. Q. Bakker, K. Weijer, P. C. Res, and H. Spits. 1997. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186:1597.
41. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553.
42. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
43. Hamann, D., M. T. Roos, and R. A. van Lier. 1999. Faces and phases of human CD8 T-cell development. Immunol. Today. 20:177.
44. Dunbar, P. R., C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, et al. 2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:6644.
45. + T cells without selection of higher affinity TCR. Nat. Immunol. 2:711.
46. Lawson, T. M., S. Man, E. C. Wang, S. Williams, N. Amos, G. M. Gillespie, P. A. Moss, and L. K. Borysiewicz. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. Int. Immunol. 13:1383.
47. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.
48. van Driel, W. J., M. E. Ressing, G. G. Kenter, R. M. Brandt, E. J. Krul, A. B. van Rossum, E. Schuuring, R. Offringa, T. Bauknecht, A. Tamm-Hermelink, et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35:946.
49. Ressing, M. E., W. J. van Driel, R. M. Brandt, G. G. Kenter, J. H. de Jong, T. Bauknecht, G. J. Fleuren, P. Hoogerhout, R. Offringa, A. Sette, et al. 2000. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 23:255.
50. Szmania, S., A. Galloway, M. Bruorton, P. Musk, G. Aubert, A. Arthur, H. Pyle, N. Hensel, N. Ta, L. Lamb, Jr., et al. 2001. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 98:505.
51. + T cells specific for EBV in healthy virus cancers. J. Immunol. 162:1827.
52. Dunbar, P. R., G. S. Ogg, J. Chen, N. Rust, B. P. van der, and V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8:413.
53. Natale, C., T. Giannini, A. Lucchese, and D. Kanduc. 2000. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol. Cell Biol. 78:580.
54. Jochmus, I., W. Osen, A. Altmann, G. Buck, B. Hofmann, A. Schneider, L. Gissmann, and H. G. Rammensee. 1997. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol. 78:1689.
55. Busch, D. H., and E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189:701.
56. Kessels, H. W., D. B. van, H. Spits, E. Hooijberg, and T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97:14578.
57. Harley, C. B., A. B. Futcher, and C. W. Greider. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345:458.
58. Hahn, W. C., C. M. Counter, A. S. Lundberg, R. L. Beijersbergen, M. W. Brooks, and R. A. Weinberg. 1999. Creation of human tumour cells with defined genetic elements. Nature 400:464.
59. + T lymphocyte immortalization. J. Immunol. 165:4978.